Activation of caspase pathways during iron chelator-mediated apoptosis.
Iron chelators have traditionally been used in the treatment of iron overload. Recently, chelators have also been explored for their ability to limit oxidant damage in cardiovascular, neurologic, and inflammatory disease as well as to serve as anti-cancer agents. To determine the mechanism of cell death induced by iron chelators, we assessed the time course and pathways of caspase activation during apoptosis induced by iron chelators. We report that the chelator tachpyridine sequentially activates caspases 9, 3, and 8. These caspases were also activated by the structurally unrelated chelators dipyridyl and desferrioxamine. The critical role of caspase activation in cell death was supported by microinjection experiments demonstrating that p35, a broad spectrum caspase inhibitor, protected HeLa cells from chelator-induced cell death. Apoptosis mediated by tachpyridine was not prevented by blocking the CD95 death receptor pathway with a Fas-associated death domain protein (FADD) dominant-negative mutant. In contrast, chelator-mediated cell death was blocked in cells microinjected with Bcl-XL and completely inhibited in cells microinjected with a dominant-negative caspase 9 expression vector. Caspase activation was not observed in cells treated with N-methyl tachpyridine, an N-alkylated derivative of tachpyridine which lacks an ability to react with iron. These results suggest that activation of a mitochondrial caspase pathway is an important mechanism by which iron chelators induce cell death.
Greene
Bryan T
BT
Department of Cancer Biology, and the Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Thorburn
Jackie
J
Willingham
Mark C
MC
Thorburn
Andrew
A
Planalp
Roy P
RP
Brechbiel
Martin W
MW
Jennings-Gee
Jamie
J
Wilkinson
John
J
Torti
Frank M
FM
Torti
Suzy V
SV
D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D020169:Caspases / Q000378:metabolism*; D003514:Cyclohexylamines / Q000494:pharmacology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004789:Enzyme Activation; D006367:HeLa Cells; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology; D051020:bcl-X Protein
C494811:BCL2L1 protein, human; D003514:Cyclohexylamines; D015853:Cysteine Proteinase Inhibitors; D007502:Iron Chelating Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D011725:Pyridines; D051020:bcl-X Protein; C114047:tachpyr; D020169:Caspases